Cefroxadine(CGP-9000)にかんする臨床的研究 (Cefroxadine(CGP-9000,CXD)<特集>)

概要

論文の詳細を見る
Cefroxadine (CGP-9000, CXD) a new oral semisynthetic cephalosporin antibiotic was studied with respect to its antibacterial activity, absorption, excretion and clinical effects, and the following results were obtained: 1) Antibacterial activity: Minimam inhibitory concentration of CXD was 6.25-100≤μ/ml for E. coli, 3.13-100≤μ/ml for Klebsiella pneumoniae, 3.13-50≤7mu;g/ml for Proteus mirabilis, 6.25-100≤μg/ml for Indole positive Proteus, 12.5-100≤μg/ml for Enterobacter cloacae, 100≤μg/ml for Serratia marcescens. Antibacterial activity of CXD against gram-negative bacteria was similar to cephalxin and cefradine. 2) Serum levels and urinary excretion: CXD was administered orally in a dose of 250 or 500mg in healthy volunteers, and peak serum levels were 6.17, 13.3μg/ml after 1hour, and serum half life of the drug was 0.75, 0.93 hours, respectively. The mean urinary recovery of CXD was 74.9% in 6 hours after 500mg oral administration in the healthy volunteers. 3) Clinical results: CXD was clinically applied to 27 cases of bacterial infections, including 4 cases of respitatory tract in fections, 1 case of cholecystitis and 22 cases of urinary tract infections. The results obtained were excellent in 1 case, good in 23 cases and poor in 3 cases. No marked side effects were observed with CXD administration.
公益社団法人日本化学療法学会の論文